Efficacy of posaconazole in murine experimental sporotrichosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2273-2277

  Fernández Silva, Fabiola ^a   Capilla, Javier ^b   Mayayo, Emilio ^a   Guarro, Josep ^b  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

POSACONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPOROTHRIX SCHENCKII; SPOROTRICHOSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HISTOCYTOCHEMISTRY; LIVER; MALE; MICE; MICROBIAL SENSITIVITY TESTS; SPECIES SPECIFICITY; SPOROTHRIX; SPOROTRICHOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TRIAZOLES;

EID: 84860134493     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05376-11     Document Type: Article

References (26)

1. Al-Tawfiq JA, Wools KK. 1998. Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection. Clin. Infect. Dis. 26:1403-1406. (Pubitemid 28270172)
2. Arrillaga-Moncrieff I, et al. 2009. Different virulence levels of the species of Sporothrix in a murine model. Clin. Microbiol. Infect. 15:651-655.
3. Barroso Pereira JC, et al. 2008. Disseminated sporotrichosis - clinical case and discussion. Rev. Port. Pneumol. 14:443-449.
4. Reference deleted.
5. Bonifaz A, Vazquez-Gonzalez D. 2010. Sporotrichosis: an update. G. Ital. Dermatol. Venereol. 145:659-673.
6. Reference deleted.
7. Calvo E, Pastor FJ, Rodríguez MM, Pujol I, Guarro J. 2010. Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii. Antimicrob. Agents Chemother. 54:4074-4077.
8. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard - second edition. Document M38-A2. CLSI, Wayne, PA.
9. de Lima RF, Schäffer GV, Borba Cde M. 2003. Variants of Sporothrix schenckii with attenuated virulence for mice. Microbes Infect. 5:933-938.
10. Dixon DM, Duncan RA, Hurd NJ. 1992. Use of a mouse model to evaluate clinical and environmental isolates of Sporothrix spp. from the largest U.S. epidemic of sporotrichosis. J. Clin. Microbiol. 30:951-954.
11. Ewing GE, Bosl GJ, Peterson PK. 1980. Sporothrix schenckii meningitis in a farmer with Hodgkin's disease. Am. J. Med. 68:455-457. (Pubitemid 10130392)
12. Galhardo MC, et al. 2008. Molecular epidemiology and antifungal susceptibility patterns of Sporothrix schenckii isolates from a cat-transmitted epidemic of sporotrichosis in Rio de Janeiro, Brazil. Med. Mycol. 46:141-151. (Pubitemid 351372333)
13. Gutierrez-Galhardo MC, et al. 2010. Disseminated sporotrichosis as a manifestation of immune reconstitution inflammatory syndrome. Mycoses 53:78-80.
14. Gutierrez-Galhardo MC, Zancope-Oliveira RM, Monzon A, Rodriguez- Tudela JL, Cuenca-Estrella M. 2010. Antifungal susceptibility profile in vitro of Sporothrix schenckii in two growth phases and by two methods: microdilution and E-test. Mycoses 53:227-231.
15. Hardman S, Stephenson I, Jenkins DR, Wiselka MJ, Johnson EM. 2005. Disseminated Sporothrix schenckii in a patient with AIDS. J. Infect. 51:73-77.
16. Kan VL, Bennett JE. 1988. Efficacies of four antifungal agents in experimental murine sporotrichosis. Antimicrob. Agents Chemother. 32:1619-1623. (Pubitemid 18267603)
17. Kauffman CA. 1999. Sporotrichosis. Clin. Infect. Dis. 29:231-236.
18. Kauffman CA, Bustamante B, Chapman SW, Pappas PG. 2007. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 45:1255-1265. (Pubitemid 351411897)
19. Kohler LM, Hamdan JS, Ferrari TC. 2007. Successful treatment of a disseminated Sporothrix schenckii infection and in vitro analysis for antifungal susceptibility testing. Diagn. Microbiol. Infect. Dis. 58:117-120. (Pubitemid 46694263)
20. Marimon R, et al. 2007. Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest. J. Clin. Microbiol. 45:3198-3206. (Pubitemid 47585640)
21. Marimón R, et al. 2008. In vitro antifungal susceptibilities of five species of Sporothrix. Antimicrob. Agents Chemother. 52:732-734. (Pubitemid 351170853)
22. Mauermann ML, Klein CJ, Orenstein R, Dyck PJ. 2007. Disseminated sporotrichosis presenting with granulomatous inflammatory multiple mononeuropathies. Muscle Nerve 36:866-872. (Pubitemid 350246938)
23. Rodríguez MM, et al. 2010. Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob. Agents Chemother. 54:1665-1669.
24. Salas VFJ, Rodríguez MM, Calvo E, Mayayo E, Guarro J. 2011. In vitro activity and in vivo efficacy of posaconazole in treatment of murine infections by different isolates of the Aspergillus terreus complex. Antimicrob. Agents Chemother. 55:676-679.
25. Silveira CP, et al. 2009. MICs and minimum fungicidal concentrations of amphotericin B, itraconazole, posaconazole and terbinafine in Sporothrix schenckii. J. Med. Microbiol. 58:1607-1610.
26. Vilela R, Souza GF, Fernandes Cota G, Mendoza L. 2007. Cutaneous and meningeal sporotrichosis in a HIV patient. Rev. Iberoam. Micol. 24: 161-163. (Pubitemid 47025156)